How rare disease drugmakers build market protection that no generic can touch — and what every analyst needs to know […]

The Patent Cliff Is Not an Event. It’s a Calendar. Every biologic drug that ever earned blockbuster status is on

Across hundreds of DrugChatter queries, a clear pattern emerges: patients and caregivers are not just asking about drugs—they’re asking what

The Evergreening Problem, Defined Precisely Evergreening is not a conspiracy. It is a rational economic strategy executed by legal means,

The blockbuster drug model has a built-in expiration date. From the moment a pharmaceutical company files its first patent, the

Part One: What GPT-Rosalind Is and What OpenAI Is Selling The Model Architecture GPT-Rosalind is the first in what OpenAI

A systematic, intelligence-led playbook for commercial and market access vendors targeting pre-LOE mandates with health plans, PBMs, IDNs, and brand

The launch of OpenAI GPT-Rosalind on April 17, 2026, marks the end of the traditional patent cliff as a predictable

The Generic Entry Problem Nobody States Plainly Every branded pharmaceutical product has a clock on it. The moment the FDA